MediWound Ltd. (NASDAQ:MDWD) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 08:30 am ET

Previous

MediWound Ltd. (NASDAQ:MDWD) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning, ladies and gentlemen, and welcome to the Q2 MediWound 2020 conference call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Jeremy Feffer. Please go ahead, sir.

Executive
Jeremy Feffer

Thank you, Tiffany, and good morning, everyone. Earlier today, MediWound issued a press release announcing financial results and provided a business update for the second quarter of 2020. You may access that release on the company's website under the Investors tab.

With us today are Sharon Malka, Chief Executive Officer; and Boaz Gur-Lavie, Chief Financial Officer. Following management's prepared remarks, we will open the call for Q&A.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound. The Company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise.

Participants are directed to cautionary notes set forth in today's press release as well as the risk factors set forth in MediWound's annual report filed with the SEC for factors that could cause the actual results to differ materially from those anticipated in the forward-looking statements. Conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.

Now, I would like to turn over the call to Sharon Malka, Chief Executive Officer. Sharon?

Executive
Sharon Malka

Thank you, Jeremy. Good morning and good afternoon to our listeners in Israel. Thank you, everyone, for joining us today on our second quarter 2020 earnings call, which will provide business and financial updates. It has been an unprecedented first half unlike we or anyone could have anticipated. While the COVID-19 pandemic caused a never-seen disruption to humanity, resulting with a significant adverse impact on international and local trade and business, we truly believe we overcame many of these challenges and have made a tremendous progress recently. This quarter, we remained committed to execution and filed our NexoBrid BLA as planned, resumed patients' enrollment in our EscharEx trial, and continued our efforts to expand sales worldwide, all while ensuring the safety and well-being of our employees, healthcare providers and patients. We are looking forward to a very busy second half filled with the continued execution and progress.

Let me now provide more detail and review of what took place during the second quarter. Over the past several months,